Form 4: Amgen EVP Sells 6,879 Shares in Pre-Planned Transaction

Amgen's Executive Vice President of Global Commercial Operations, Murdo Gordon, reported the sale of 6,879 shares of common stock as part of a pre-arranged 10b5-1 plan.

Summary

• Murdo Gordon, Amgen's Executive Vice President of Global Commercial Operations, sold 6,879 shares of Amgen common stock.
• The transaction occurred on November 12, 2025.
• The shares were sold at an average price of $336.8326 per share, with prices ranging from $336.7301 to $337.0500.
• The sale was conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan, indicating a scheduled transaction.
• Following the transaction, Murdo Gordon beneficially owns 41,923 shares of Amgen common stock directly.
• The beneficially owned shares include 647 Dividend Equivalents (DEs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which are credited to unvested Restricted Stock Units (RSUs) and paid out in shares on a one-to-one basis upon vesting.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale executed under a pre-arranged 10b5-1 plan, which typically indicates a planned liquidity event rather than a reaction to new information, thus having a neutral sentiment.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a reaction to recent events, which often mitigates negative perceptions of insider selling.

Negatives

• An insider sale, even if pre-planned, results in a reduction of the executive's direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The price reported is an average price. The prices ranged from $336.7301 to $337.0500 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
• These shares include 647 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Industry Context

This Form 4 filing details a specific insider transaction and does not provide information relevant to broader industry trends or competitor analysis.

Stakeholder Impact

• Shareholders: A minor reduction in an executive's direct ownership, but mitigated by the fact that it was a pre-planned transaction under a 10b5-1 plan, which generally reduces concerns about opportunistic selling.

Key Dates

Keywords

Amgen, AMGN, Murdo Gordon, insider sale, Form 4, 10b5-1 plan, executive compensation, common stock